Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price was up 8.3% during mid-day trading on Tuesday . The stock traded as high as C$0.07 and last traded at C$0.07. 77,822 shares traded hands during trading, an increase of 63% from the average session volume of 47,821 shares. The stock had previously closed at C$0.06.
Hemostemix Stock Down 14.3%
The company has a current ratio of 0.24, a quick ratio of 0.48 and a debt-to-equity ratio of -66.09. The company has a market capitalization of C$12.30 million, a P/E ratio of -3.00 and a beta of 0.21. The stock has a 50 day moving average price of C$0.06 and a 200 day moving average price of C$0.07.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Further Reading
- Five stocks we like better than Hemostemix
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
